Chrysos Accelerates Global Growth with Record PhotonAssay Deployments
Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.
- Record sample volumes boost revenue to $28.9 million YTD
- Global footprint expands with 41 PhotonAssay units deployed
- New contracts secured with Allied Gold, Acrux Gold, and Bureau Veritas
- FY26 revenue guidance reaffirmed at $80-90 million
- Strong cash position supports ongoing deployments and innovation
Robust Operational Performance in FY25
Chrysos Corporation has delivered a strong performance in the 2025 financial year, underpinned by steady operational execution and strategic international expansion. The company’s flagship PhotonAssay technology, which offers faster, safer, and more accurate gold analysis, continues to gain traction among leading miners and laboratories worldwide.
Utilisation rates remain healthy, and customer feedback highlights the technology’s reliability and efficiency. Chrysos has also enhanced its deployment model, streamlining installations and embedding local technical teams to provide timely support; a critical factor as the company scales its global presence.
Expanding Global Footprint and Partnerships
Chrysos now operates 41 PhotonAssay units across key mining regions including Australia, EMEA, and the Americas. Notably, the company’s partnership with Bureau Veritas has unlocked entry into South America, a major gold mining hub. Additional deployments this year include new units at Thunder Bay, Ontario, and the Norseman Gold Mine in Australia, alongside upcoming installations in Scotland, Ghana, Chile, Canada, and West Africa.
The recent memorandum of understanding with Allied Gold marks a significant milestone, with plans for full adoption of PhotonAssay technology across their mine sites and hub laboratories. This deal exemplifies Chrysos’ strategy to deepen existing partnerships while securing new contracts to drive growth.
Financial Momentum and Outlook
Revenue for the year to date reached $28.9 million, supported by a fee-per-sample business model that benefits directly from increased sample throughput. The contribution from the AAC segment has notably risen to 26.4% of revenue, up from 15.3% in FY25, reflecting diversification in Chrysos’ revenue streams.
Looking ahead, Chrysos reiterates its FY26 guidance of $80 to $90 million in revenue and $20 to $27 million in EBITDA. The company’s strong cash reserves of $75.7 million, combined with positive operating cash flow, provide a solid foundation to support ongoing deployments and technology advancements.
Strategic Priorities and Innovation Focus
Chrysos remains focused on delivering its contracted pipeline, accelerating global deployments, and enhancing operational efficiency. The company is also committed to advancing its technology roadmap to maintain leadership in assay innovation, ensuring it stays ahead in a competitive and evolving market.
With the gold market showing sustained strength, Chrysos is well positioned to capitalize on growing demand for faster and more accurate assay solutions, reinforcing its role as a trusted partner to the mining industry worldwide.
Bottom Line?
Chrysos’ expanding global footprint and robust financial outlook set the stage for continued growth amid a buoyant gold market.
Questions in the middle?
- How will Chrysos manage supply chain and installation challenges as deployments accelerate?
- What impact will the increased AAC revenue share have on overall margins?
- Can Chrysos sustain its technology leadership against emerging assay competitors?
